View Older Stories View More Recent Stories

Dec 29, 2025 09:00AM ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of “100 Most Influential People in Oncology in 2025”
Dec 16, 2025 09:01AM ImmunityBio's ANKTIVA shows 96% survival in bladder cancer study
Dec 16, 2025 09:00AM ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer
Dec 12, 2025 06:10AM ImmunityBio gets european drug agency nod for bladder cancer treatment
Dec 12, 2025 06:10AM ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in
Nov 13, 2025 09:00AM New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations
Nov 4, 2025 10:12PM Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024
Sep 8, 2025 08:30AM ImmunityBio reports ANKTIVA therapy reverses lymphopenia in lung cancer
Sep 8, 2025 08:30AM ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy
Aug 26, 2025 08:31AM ImmunityBio reports early trial results in brain cancer treatment
Aug 26, 2025 08:30AM Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA®, NK Cell Therapy Plus Optu
Aug 19, 2025 08:30AM ImmunityBio launches phase 2 trial of ANKTIVA for long COVID treatment
Aug 19, 2025 08:30AM ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID
Aug 13, 2025 08:31AM ImmunityBio reports complete responses in lymphoma trial with CAR-NK therapy
Aug 13, 2025 08:30AM ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy
Aug 11, 2025 08:30AM ImmunityBio Announces Houston’s Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients
Aug 5, 2025 07:00AM ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code
Jul 25, 2025 06:06AM ImmunityBio raises $80 million from institutional investors
Jul 25, 2025 06:03AM ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors
Jul 25, 2025 06:00AM ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates
Jul 7, 2025 09:43PM UK MHRA Approves ImmunityBio’s ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
Jun 3, 2025 08:45AM ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer
Jun 2, 2025 09:02AM ImmunityBio (IBRX) receives FDA Expanded Access for Cancer BioShield platform
Jun 2, 2025 09:00AM ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors
May 27, 2025 08:00AM ImmunityBio, Saudi Arabia’s Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East
May 12, 2025 06:30AM ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code
May 5, 2025 07:51AM ImmunityBio (IBRX) receives Refusal to File letter from FDA for sBLA for use of ANKTIVA plus Bacillus Calmette-Guerin
May 5, 2025 06:30AM ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency’s Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inc
Apr 28, 2025 08:30AM Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best i
Apr 21, 2025 04:21PM ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting
Apr 15, 2025 08:01AM ImmunityBio (IBRX) Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia
Apr 15, 2025 08:00AM ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia
Apr 8, 2025 07:32AM ImmunityBio (IBRX) Announces Execution of $75 Million Equity Financing with an Institutional Investor
Apr 8, 2025 07:30AM ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor
Apr 7, 2025 05:00AM ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch
Mar 26, 2025 06:00AM ImmunityBio to Host Investor Day
Mar 13, 2025 09:00AM ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching
Mar 3, 2025 07:30AM ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024
Feb 28, 2025 09:11AM ImmunityBio (IBRX) Receives FDA RMAT Designation for ANKTIVA and CAR-NK
Feb 27, 2025 07:10PM ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapse
Feb 19, 2025 09:01AM ImmunityBio (IBRX): FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage
Feb 19, 2025 09:00AM FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage
Feb 13, 2025 03:06PM ImmunityBio (IBRX) Announces UK MHRA Accepted MAA for ANKTIVA for Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma
Feb 13, 2025 03:05PM ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle I
Jan 29, 2025 08:39AM ImmunityBio (IBRX) Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer
Jan 29, 2025 08:30AM ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer
Jan 27, 2025 09:00AM ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer C
Jan 16, 2025 03:03PM ImmunityBio (IBRX) Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency (earlier)
Jan 15, 2025 05:20PM ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom
Jan 15, 2025 05:20PM ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency
View More Recent Stories View Older Stories